Table 2 Medication in the probiotic and placebo group during COVID-19

NSAID, n (%)

7 (20.6)

12 (33.3)

0.239^a

median days (IQR)

3.0 (1.0–7.0)

4.5 (3.0–6.5)

0.482^b

Antitussives, n (%)

15 (44.1)

19 (52.8)

0.474

median days (IQR)

5.0 (4.0–7.0)

7.0 (5.0–8.0)

0.241

Nasal decongestants, n (%)

5 (14.7)

3 (8.3)

0.408

median days (IQR)

5.0 (4.0–5.0)

5.0 (4.0–5.0)

0.785

Throat antiseptics, n (%)

7 (20.6)

11 (30.6)

0.347

median days (IQR)

5.0 (4.0–5.0)

6.0 (5.0–8.0)

0.044

Antispasmodics, n (%)

0 (0.0)

6 (16.7)

0.018

median days (IQR)

-

4.0 (2.0–5.0)

NA^c

Antidiarrheal, n (%)

1 (2.9)

1 (2.8)

0.968

median days (IQR)

1.0 (-)

1.0 (-)

NA

Antiplatelet, n (%)

1 (2.9)

1 (2.8)

0.968

median days (IQR)

11.0 (-)

4 (-)

NA

Herbs, n (%)

1 (2.9)

2 (5.6)

0.593

median days (IQR)

1.0 (-)

14.0 (6.0–22.0)

NA